Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Anticancer pharmaceutical composition

A technology of anticancer drugs and compositions, which is applied in the direction of drug combinations, antineoplastic drugs, and pharmaceutical formulations, and can solve problems such as not being administered at the same time, and achieve the effects of reducing the incidence of adverse reactions, reducing dosage, and reducing toxic and side effects

Active Publication Date: 2015-07-22
LUNAN PHARMA GROUP CORPORATION
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Shang Chunying et al. disclosed that paclitaxel combined with cisplatin in the treatment of advanced non-small cell lung cancer (Chinese Medicine Guide, February 2010, Volume 8, Issue 5, pages 55-56) Technical solution for non-small cell lung cancer, paclitaxel 135mg / m 2 , intravenous infusion for 3 hours on the first day, cisplatin 30mg / m 2 , Intravenous infusion on the first 1-3 days, 4 weeks as a cycle, take anti-allergic measures before paclitaxel infusion, but paclitaxel and cisplatin are not intravenous infusion at the same time
He Anbing et al. published the clinical observation of docetaxel combined with oxaliplatin in the treatment of advanced non-small cell lung cancer (Modern Oncology, January 2010, Volume 18, No. 01, Page 100-101). Combined with oxaliplatin in the treatment of advanced non-small cell lung cancer technical scheme, docetaxel 35mg / m 2 , intravenous infusion for 3 hours on the first and eighth days; oxaliplatin 130mg / m 2 , intravenous infusion for 2 hours on the first day, once every 3 weeks as a cycle, but docetaxel and oxaliplatin are not administered at the same time
In the technical solutions disclosed in the above two documents, paclitaxel or docetaxel and platinum drugs are not administered in the form of a pharmaceutical composition

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anticancer pharmaceutical composition
  • Anticancer pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Embodiment 1 pharmaceutical composition microemulsion preparation of the present invention

[0026] Arctigenin 0.01g

[0027] Paclitaxel 10g

[0028] peppermint oil 35g

[0029] Polyoxyethylene-23-lauryl ether 60g

[0030] 1,2-propanediol 30g

[0031] Preparation process: Weigh the prescription amount of peppermint oil, polyoxyethylene-23-lauryl ether, and 1,2-propylene glycol, mix and stir evenly, then add arctigenin and paclitaxel to dissolve, and ultrasonic treatment can also be used to speed up the dissolution and obtain clarification The concentrated solution is arctigenin and paclitaxel microemulsion concentrate. The particle size was measured by a laser particle size analyzer, and the average particle size was 15nm.

Embodiment 2

[0032] Embodiment 2 pharmaceutical composition microemulsion preparation of the present invention

[0033] Arctigenin 10g

[0034] Paclitaxel 0.1g

[0035] Hydrogenated Coco Glycerides 5g

[0036] Lauroyl macrogol-32-glycerides 20g

[0037] 1,2-propanediol 5g

[0038] Polyethylene glycol 3350 20g

[0039] Preparation process: Weigh the prescription amount of hydrogenated cocoglyceride, lauroyl macrogol-32-glyceride, 1,2-propylene glycol, polyethylene glycol 3350, mix and stir evenly, then add arctigenin and paclitaxel to dissolve , can also be ultrasonically treated to accelerate the dissolution to obtain a clear concentrate, which is arctigenin and paclitaxel microemulsion concentrate. The particle size was measured by a laser particle size analyzer, and the average particle size was 40nm.

Embodiment 3

[0040] Embodiment 3 pharmaceutical composition microemulsion preparation of the present invention

[0041] Arctigenin 10g

[0042] Paclitaxel 10g

[0043] peppermint oil 35g

[0044] Polyoxyethylene-23-lauryl ether 60g

[0045] 1,2-propanediol 30g

[0046] The preparation process is the same as in Example 2. The particle size was measured by a laser particle size analyzer, and the average particle size was 36nm.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
Login to View More

Abstract

The invention belongs to the technical field of medicine and pharmacy and relates to an anticancer pharmaceutical composition. The composition contains burdock aglycone and a paclitaxel drug. The pharmaceutical composition has a synergistic inhibitory effect on non-small-cell lung carcinoma as compared with either component alone. The invention also provides microemulsions and injections containing the pharmaceutical composition.

Description

technical field [0001] The invention relates to an anticancer drug composition, in particular to a drug composition containing arctigenin and paclitaxel drugs. Background technique [0002] At present, cancer is one of the major diseases that seriously affect human health and threaten human life. Cancer, cardiovascular and cerebrovascular diseases and accidents constitute the three major causes of death in all countries in the world today. Therefore, the World Health Organization and the health departments of governments of various countries have listed conquering cancer as a top priority. There are three main ways to treat cancer in the world. One is to use surgical resection to remove the diseased tissue to prevent the spread of cancer cells; the other is to use chemotherapy or radiotherapy to kill cancer cells; the third is to use drugs to treat it. Adopt the method for surgical excision to increase patient's misery, hurt its vitality, and expense is huge. Chemotherapy...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/365A61K31/337A61P35/00
Inventor 赵志全商庆节
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com